A tetrazine-responsive isonitrile-caged photosensitiser for site-specific photodynamic therapy

J Control Release. 2023 Jan:353:663-674. doi: 10.1016/j.jconrel.2022.12.015. Epub 2022 Dec 14.

Abstract

We report herein a versatile and efficient bioorthogonal strategy to actualise targeted delivery and site-specific activation of photosensitisers for precise antitumoural photodynamic therapy. The strategy involved the use of an isonitrile-caged distyryl boron dipyrromethene-based photosensitiser, labelled as NC-DSBDP, of which the photoactivities could be specifically activated upon conversion of the meso ester substituent to carboxylate initiated by the [4 + 1] cycloaddition with a tetrazine derivative. By using two tetrazines conjugated with a galactose moiety or the GE11 peptide, labelled as gal-Tz and GE11-Tz, we could selectively label the cancer cells overexpressed with the asialoglycoprotein receptor and the epidermal growth factor receptor respectively. Upon encountering the internalised NC-DSBDP, these tetrazines triggered the "ester-to-carboxylate" transformation of this compound, activating its fluorescence and reactive oxygen species generation inside the target cells. The bioorthogonal activation was also demonstrated in vivo, leading to effective photo-eradication of the tumour in nude mice.

Keywords: Bioorthogonal chemistry; Boron dipyrromethene; Isonitrile; Photodynamic therapy; Tetrazine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Heterocyclic Compounds* / chemistry
  • Mice
  • Mice, Nude
  • Neoplasms* / drug therapy
  • Photochemotherapy*
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / therapeutic use

Substances

  • Photosensitizing Agents
  • Heterocyclic Compounds